Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02552732 · ClinicalTrials.gov registry record · NA
Nasal High Flow Therapy 30 Day Readmission Study
A NA study, sponsored by Fisher and Paykel Healthcare.
- Terminated
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02552732 is a NA study that was terminated before completion, run by Fisher and Paykel Healthcare. The registered enrollment target is 29 participants.
The verdict
NCT02552732, a NA study, was terminated before completion, sponsored by Fisher and Paykel Healthcare.
- TERMINATED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.
Interventions
- DEVICE NHF with or without Oxygen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-05-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02552732
The ClinicalTrials.gov registry entry for NCT02552732 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fisher and Paykel Healthcare, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NHF with or without Oxygen is the first listed.
NCT02552732 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02552732 about?
NCT02552732 is a clinical study titled "Nasal High Flow Therapy 30 Day Readmission Study". The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate th...
What is the current status of trial NCT02552732?
This trial is currently terminated. It is a NA study. The enrollment target is 29 participants. The study started on 2015-11. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT02552732?
The interventions under investigation include: NHF with or without Oxygen (DEVICE).
Who is sponsoring clinical trial NCT02552732?
This trial is sponsored by Fisher and Paykel Healthcare, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.